Osteoarthritis: Mechanistic Insights, Senescence, and Novel Therapeutic Opportunities
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Identificadores![](/xmlui/themes/Mirage2//images/despl_identif.png)
Identificadores
Visualización o descarga de ficheros![](/xmlui/themes/Mirage2//images/despl_contenidos.png)
Visualización o descarga de ficheros
Fecha de publicación
2022-03-15Título de revista
Bioelectricity
Tipo de contenido
Artigo
DeCS
conexina 43 | terapéutica | cartílago articular | condrocitosMeSH
Therapeutics | Cartilage, Articular | Connexin 43 | ChondrocytesResumen
Osteoarthritis (OA) is the most common joint disease. In the last years, the research community has focused on
understanding the molecular mechanisms that led to the pathogenesis of the disease, trying to identify different
molecular and clinical phenotypes along with the discovery of new therapeutic opportunities. Different types of
cell-to-cell communication mechanisms have been proposed to contribute to OA progression, including
mechanisms mediated by connexin43 (Cx43) channels or by small extracellular vesicles. Furthermore, changes
in the chondrocyte phenotype such as cellular senescence have been proposed as new contributors of the OA
progression, changing the paradigm of the disease. The use of different drugs able to restore chondrocyte
phenotype, to reduce cellular senescence and senescence-associated secretory phenotype components, and to
modulate ion channel activity or Cx43 appears to be promising therapeutic strategies for the different types of
OA. In this review, we aim to summarize the current knowledge in OA phenotypes related with aging and tissue
damage and the new therapeutic opportunities currently available.
![](/xmlui/themes/Mirage2//images/final_lines.png)